- Featured Product
- KD/KO Validated
XIAP Polyklonaler Antikörper
XIAP Polyklonal Antikörper für WB, IHC, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, IHC, CoIP, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 10037-1-Ig
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in WB | RAW 264.7-Zellen, C6-Zellen, COLO 320-Zellen, HeLa-Zellen, HepG2-Zellen, Jurkat-Zellen, NIH/3T3-Zellen, Raji-Zellen |
| Erfolgreiche Detektion in IHC | humanes Pankreaskarzinomgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunhistochemie (IHC) | IHC : 1:20-1:200 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| KD/KO | See 2 publications below |
| WB | See 45 publications below |
| IHC | See 11 publications below |
| CoIP | See 1 publications below |
Produktinformation
10037-1-Ig bindet in WB, IHC, CoIP, ELISA XIAP und zeigt Reaktivität mit human, Maus, Ratten
| Getestete Reaktivität | human, Maus, Ratte |
| In Publikationen genannte Reaktivität | human, Maus, Ratte |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | XIAP fusion protein Ag0022 |
| Vollständiger Name | X-linked inhibitor of apoptosis |
| Berechnetes Molekulargewicht | 60 kDa |
| Beobachtetes Molekulargewicht | 45-57 kDa |
| GenBank-Zugangsnummer | BC032729 |
| Gene symbol | XIAP |
| Gene ID (NCBI) | 331 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Protein-A-Reinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
XIAP, also named as API3, BIRC4 and IAP3, belongs to the IAP family. It has E3 ubiquitin-protein ligase activity. It mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. XIAP is an inhibitor of caspase-3, -7 and -9. It mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B. XIAP is an apoptotic suppressor. It is ubiquitinated and degraded by the proteasome in apoptotic cells. The MW of XIAP is 45-56 kDa.
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| WB protocol for XIAP antibody 10037-1-Ig | Protokoll herunterladen |
| IHC protocol for XIAP antibody 10037-1-Ig | Protokoll herunterladenl |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
Nat Commun Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. | ||
Cancer Res DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer | ||
Cancer Res An ATM/TRIM37/NEMO axis counteracts genotoxicity by activating nuclear-to-cytoplasmic NF-κB signaling. | ||
EMBO Rep XIAP-mediated degradation of IFT88 disrupts HSC cilia to stimulate HSC activation and liver fibrosis
| ||
Acta Pharmacol Sin Aspirin modulates succinylation of PGAM1K99 to restrict the glycolysis through NF-κB/HAT1/PGAM1 signaling in liver cancer. | ||
Int J Nanomedicine Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. |





